Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck

  • 9 Accesses


Fibroblastic and myofibroblastic neoplasms of the head and neck encompass a group of rare tumor types with often overlapping clinicopathologic features that range in biologic potential from benign to overtly malignant. Even neoplasms with no metastatic potential may provide significant therapeutic challenges in this region due to the unique anatomy of the head and neck. This review will cover the following entities, highlighting important clinical aspects of each neoplasm and then focusing on their characteristic histomorphology, immunophenotype, and molecular alterations: nodular and cranial fasciitis, fibrous hamartoma of infancy, nasopharyngeal angiofibroma, nuchal-type and Gardner fibromas, desmoid fibromatosis, dermatofibrosarcoma protuberans and giant cell fibroblastoma, solitary fibrous tumor, inflammatory myofibroblastic tumor, low-grade myofibroblastic sarcoma, infantile fibrosarcoma, low-grade fibromyxoid sarcoma, and sclerosing epithelioid fibrosarcoma. While some of these neoplasms characteristically arise in the head and neck, others are rarely described in this anatomic region and may therefore be particularly difficult to recognize. Distinction between these entities, however, is crucial, particularly as the molecular pathogenetic basis for these neoplasms are being rapidly elucidated, in some instances allowing for targeted therapeutic approaches.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8


  1. 1.

    Bernstein KE, Lattes R. Nodular (pseudosarcomatous) fasciitis, a nonrecurrent lesion: clinicopathologic study of 134 cases. Cancer. 1982;49:1668–78.

  2. 2.

    Shimizu S, Hashimoto H, Enjoji M. Nodular fasciitis: an analysis of 250 patients. Pathology. 1984;16:161–6.

  3. 3.

    Montgomery EA, Meis JM. Nodular fasciitis. Its morphologic spectrum and immunohistochemical profile. Am J Surg Pathol. 1991;15:942–8.

  4. 4.

    Lu L, Lao IW, Liu X, Yu L, Wang J. Nodular fasciitis: a retrospective study of 272 cases from China with clinicopathologic and radiologic correlation. Ann Diagn Pathol. 2015;19:180–5.

  5. 5.

    Thompson LD, Fanburg-Smith JC, Wenig BM. Nodular fasciitis of the external ear region: a clinicopathologic study of 50 cases. Ann Diagn Pathol. 2001;5:191–8.

  6. 6.

    Gibson TC, Bishop JA, Thompson LDR. Parotid gland nodular fasciitis: a clinicopathologic series of 12 cases with a review of 18 cases from the literature. Head Neck Pathol. 2015;9:334–44.

  7. 7.

    Kikuchi I, Hiejima M, Inoue S. Nodular fasciitis. A spontaneously regressing tumor? J Dermatol. 1980;7:143–7.

  8. 8.

    Lauer DH, Enzinger FM. Cranial fasciitis of childhood. Cancer. 1980;45:401–6.

  9. 9.

    Alshareef M, Klapthor G, Alshareef A, Almadidy Z, Wright Z, Infinger L, et al. Pediatric cranial fasciitis: discussion of cases and systematic review of the literature. World Neurosurg. 2019;125:e829–42.

  10. 10.

    Kumon Y, Sakaki S, Sakoh M, Nakano K, Fukui K, Kurihara K. Cranial fasciitis of childhood: a case report. Surg Neurol. 1992;38:68–72.

  11. 11.

    Amary MF, Ye H, Berisha F, Tirabosco R, Presneau N, Flanagan AM. Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. Virchows Arch. 2013;463:97–8.

  12. 12.

    Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011;91:1427–33.

  13. 13.

    Patel NR, Chrisinger JSA, Demicco EG, Sarabia SF, Reuther J, Kumar E, et al. USP6 activation in nodular fasciitis by promoter-swapping gene fusions. Mod Pathol. 2017;30:1577–88.

  14. 14.

    Salib C, Edelman M, Lilly J, Fantasia JE, Yancoskie AE. USP6 gene rearrangement by FISH analysis in cranial fasciitis: a report of three cases. Head Neck Pathol. 2019.

  15. 15.

    Enzinger FM. Fibrous hamartoma of infancy. Cancer. 1965;18:241–8.

  16. 16.

    Carretto E, Dall’Igna P, Alaggio R, Siracusa F, Granata C, Ferrari A, et al. Fibrous hamartoma of infancy: an Italian multi-institutional experience. J Am Acad Dermatol. 2006;54:800–3.

  17. 17.

    Saab ST, McClain CM, Coffin CM. Fibrous hamartoma of infancy: a clinicopathologic analysis of 60 cases. Am J Surg Pathol. 2014;38:394–401.

  18. 18.

    Al-Ibraheemi A, Martinez A, Weiss SW, Kozakewich HP, Perez-Atayde AR, Tran H, et al. Fibrous hamartoma of infancy: a clinicopathologic study of 145 cases, including 2 with sarcomatous features. Mod Pathol. 2017;30:474–85.

  19. 19.

    Fletcher CD, Powell G, van Noorden S, McKee PH. Fibrous hamartoma of infancy: a histochemical and immunohistochemical study. Histopathology. 1988;12:65–74.

  20. 20.

    Park JY, Cohen C, Lopez D, Ramos E, Wagenfuehr J, Rakheja D. EGFR Exon 20 insertion/duplication mutations characterize fibrous hamartoma of infancy. Am J Surg Pathol. 2016;40:1713–8.

  21. 21.

    Ellington N, Park JY, King K, Josephs S, Rakheja D. EGFR Exon 20 insertion/duplication mutation in fibrous hamartoma of infancy with predominantly pseudoangiomatous pattern mimicking giant cell fibroblastoma. Int J Surg Pathol. 2017;25:421–4.

  22. 22.

    Neel HB, Whicker JH, Devine KD, Weiland LH. Juvenile angiofibroma: review of 120 cases. Am J Surg. 1973;126:547–56.

  23. 23.

    Witt TR, Shah JP, Sternberg SS. Juvenile nasopharyngeal angiofibroma: a 30 year clinical review. Am J Surg. 1983;146:521–5.

  24. 24.

    Glad H, Vainer B, Buchwald C, Petersen BL, Theilgaard SA, Bonvin P, et al. Juvenile nasopharyngeal angiofibromas in Denmark 1981–2003: diagnosis, incidence, and treatment. Acta Otolaryngol. 2007;127:292–9.

  25. 25.

    Boghani Z, Husain Q, Kanumuri VV, Khan MN, Sangvhi S, Liu JK, et al. Juvenile nasopharyngeal angiofibroma: a systematic review and comparison of endoscopic, endoscopic-assisted, and open resection in 1047 cases. Laryngoscope. 2013;123:859–69.

  26. 26.

    Valanzano R, Curia MC, Aceto G, Veschi S, De Lellis L, Catalano T, et al. Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumour. Gut. 2005;54:1046–7.

  27. 27.

    Schick B, Rippel C, Brunner C, Jung V, Plinkert PK, Urbschat S. Numerical sex chromosome aberrations in juvenile angiofibromas: genetic evidence for an androgen-dependent tumor? Oncol Rep. 2003;10:1251–5.

  28. 28.

    Beham A, Fletcher CD, Kainz J, Schmid C, Humer U. Nasopharyngeal angiofibroma: an immunohistochemical study of 32 cases. Virchows Arch A. 1993;423:281–5.

  29. 29.

    Hwang HC, Mills SE, Patterson K, Gown AM. Expression of androgen receptors in nasopharyngeal angiofibroma: an immunohistochemical study of 24 cases. Mod Pathol. 1998;11:1122–6.

  30. 30.

    Liu Z, Wang J, Wang H, Wang D, Hu L, Liu Q, et al. Hormonal receptors and vascular endothelial growth factor in juvenile nasopharyngeal angiofibroma: immunohistochemical and tissue microarray analysis. Acta Otolaryngol. 2015;135:51–7.

  31. 31.

    Abraham SC, Montgomery EA, Giardiello FM, Wu TT. Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas. Am J Pathol. 2001;158:1073–8.

  32. 32.

    Wemmert S, Willnecker V, Kulas P, Weber S, Lerner C, Berndt S, et al. Identification of CTNNB1 mutations, CTNNB1 amplifications, and an Axin2 splice variant in juvenile angiofibromas. Tumour Biol. 2016;37:5539–49.

  33. 33.

    Balachandran K, Allen PW, MacCormac LB. Nuchal fibroma. A clinicopathological study of nine cases. Am J Surg Pathol. 1995;19:313–7.

  34. 34.

    Coffin CM, Hornick JL, Zhou H, Fletcher CDM. Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. Am J Surg Pathol. 2007;31:410–6.

  35. 35.

    Michal M, Fetsch JF, Hes O, Miettinen M. Nuchal-type fibroma: a clinicopathologic study of 52 cases. Cancer. 1999;85:156–63.

  36. 36.

    Dahl NA, Sheil A, Knapke S, Geller JI. Gardner fibroma: clinical and histopathologic implications of germline APC mutation association. J Pediatr Hematol Oncol. 2016;38:e154–7.

  37. 37.

    Vieira J, Pinto C, Afonso M, do Bom Sucesso M, Lopes P, Pinheiro M, et al. Identification of previously unrecognized FAP in children with Gardner fibroma. Eur J Hum Genet. 2015;23:715–8.

  38. 38.

    Gnepp DR, Henley J, Weiss S, Heffner D. Desmoid fibromatosis of the sinonasal tract and nasopharynx: a clinicopathologic study of 25 cases. Cancer. 1996;78:2572–9.

  39. 39.

    de Bree E, Zoras O, Hunt JL, Takes RP, Suárez C, Mendenhall WM, et al. Desmoid tumors of the head and neck: a therapeutic challenge. Head Neck. 2014;36:1517–26.

  40. 40.

    Flucke U, Tops BBJ, van Diest PJ, Slootweg PJ. Desmoid-type fibromatosis of the head and neck region in the paediatric population: a clinicopathological and genetic study of seven cases. Histopathology. 2014;64:769–76.

  41. 41.

    Kruse AL, Luebbers HT, Grätz KW, Obwegeser JA. Aggressive fibromatosis of the head and neck: a new classification based on a literature review over 40 years (1968–2008). Oral Maxillofac Surg. 2010;14:227–32.

  42. 42.

    Fisher C, Thway K. Aggressive fibromatosis. Pathology. 2014;46:135–40.

  43. 43.

    Burke AP, Sobin LH, Shekitka KM, Federspiel BH, Helwig EB. Intra-abdominal fibromatosis. A pathologic analysis of 130 tumors with comparison of clinical subgroups. Am J Surg Pathol. 1990;14:335–41.

  44. 44.

    Zreik RT, Fritchie KJ. Morphologic spectrum of desmoid-type fibromatosis. Am J Clin Pathol. 2016;145:332–40.

  45. 45.

    Carlson JW, Fletcher CDM. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 2007;51:509–14.

  46. 46.

    Lazar AJF, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–27.

  47. 47.

    Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119:3696–702.

  48. 48.

    Le Guellec S, Soubeyran I, Rochaix P, Filleron T, Neuville A, Hostein I, et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol. 2012;25:1551–8.

  49. 49.

    Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615–20.

  50. 50.

    Jha P, Moosavi C, Fanburg-Smith JC. Giant cell fibroblastoma: an update and addition of 86 new cases from the Armed Forces Institute of Pathology, in honor of Dr. Franz M. Enzinger. Ann Diagn Pathol. 2007;11:81–8.

  51. 51.

    Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet. 2003;140:1–12.

  52. 52.

    Thway K, Noujaim J, Jones RL, Fisher C. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. Ann Diagn Pathol. 2016;25:64–71.

  53. 53.

    Dymock RB, Allen PW, Stirling JW, Gilbert EF, Thornbery JM. Giant cell fibroblastoma. A distinctive, recurrent tumor of childhood. Am J Surg Pathol. 1987;11:263–71.

  54. 54.

    Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD. Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576–87.

  55. 55.

    Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol. 2006;30:436–43.

  56. 56.

    Dal Cin P, Sciot R, de Wever I, Brock P, Casteels-Van Daele M, Van Damme B, et al. Cytogenetic and immunohistochemical evidence that giant cell fibroblastoma is related to dermatofibrosarcoma protuberans. Genes Chromosom Cancer. 1996;15:73–5.

  57. 57.

    Abbott JJ, Erickson-Johnson M, Wang X, Nascimento AG, Oliveira AM. Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol. 2006;19:1512–8.

  58. 58.

    Macarenco RS, Zamolyi R, Franco MF, Nascimento AG, Abott JJ, Wang X, et al. Genomic gains of COL1A1-PDFGB occur in the histologic evolution of giant cell fibroblastoma into dermatofibrosarcoma protuberans. Genes Chromosomes Cancer. 2008;47:260–5.

  59. 59.

    Dadone-Montaudié B, Alberti L, Duc A, Delespaul L, Lesluyes T, Pérot G, et al. Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions. Mod Pathol. 2018;31:1683–93.

  60. 60.

    Dickson BC, Hornick JL, Fletcher CDM, Demicco EG, Howarth DJ, Swanson D, et al. Dermatofibrosarcoma protuberans with a novel COL6A3-PDGFD fusion gene and apparent predilection for breast. Genes Chromosom Cancer. 2018;57:437–45.

  61. 61.

    Demicco EG, Park MS, Araujo DM, Fox PS, Bassett RL, Pollock RE, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol. 2012;25:1298–306.

  62. 62.

    Smith SC, Gooding WE, Elkins M, Patel RM, Harms PW, McDaniel AS, et al. Solitary fibrous tumors of the head and neck: a Multi-Institutional Clinicopathologic Study. Am J Surg Pathol. 2017;41:1642–56.

  63. 63.

    Kao Y-C, Lin P-C, Yen S-L, Huang S-C, Tsai J-W, Li C-F, et al. Clinicopathological and genetic heterogeneity of the head and neck solitary fibrous tumours: a comparative histological, immunohistochemical and molecular study of 36 cases. Histopathology. 2016;68:492–501.

  64. 64.

    Cox DP, Daniels T, Jordan RCK. Solitary fibrous tumor of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2010;110:79–84.

  65. 65.

    Demicco EG, Wagner MJ, Maki RG, Gupta V, Iofin I, Lazar AJ, et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Mod Pathol. 2017;30:1433–42.

  66. 66.

    Thway K, Ng W, Noujaim J, Jones RL, Fisher C. The current status of solitary fibrous tumor: diagnostic features, variants, and genetics. Int J Surg Pathol. 2016;24:281–92.

  67. 67.

    Mosquera J-M, Fletcher CDM. Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component–is this dedifferentiated SFT? Am J Surg Pathol. 2009;33:1314–21.

  68. 68.

    Mohajeri A, Tayebwa J, Collin A, Nilsson J, Magnusson L, von Steyern FV, et al. Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosom Cancer. 2013;52:873–86.

  69. 69.

    Robinson DR, Wu Y-M, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung Y-S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45:180–5.

  70. 70.

    Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45:131–2.

  71. 71.

    Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27:390–5.

  72. 72.

    Bahrami A, Lee S, Schaefer I-M, Boland JM, Patton KT, Pounds S, et al. TERT promoter mutations and prognosis in solitary fibrous tumor. Mod Pathol. 2016;29:1511–22.

  73. 73.

    Demicco EG, Wani K, Ingram D, Wagner M, Maki RG, Rizzo A, et al. TERT promoter mutations in solitary fibrous tumour. Histopathology. 2018;73:843–51.

  74. 74.

    Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995;19:859–72.

  75. 75.

    Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 2008;61:428–37.

  76. 76.

    He C-Y, Dong G-H, Yang D-M, Liu H-G. Inflammatory myofibroblastic tumors of the nasal cavity and paranasal sinus: a clinicopathologic study of 25 cases and review of the literature. Eur Arch Otorhinolaryngol. 2015;272:789–97.

  77. 77.

    Idrees MT, Huan Y, Woo P, Wang BY. Inflammatory myofibroblastic tumor of larynx: a benign lesion with variable morphological spectrum. Ann Diagn Pathol. 2007;11:433–9.

  78. 78.

    Wenig BM, Devaney K, Bisceglia M. Inflammatory myofibroblastic tumor of the larynx. A clinicopathologic study of eight cases simulating a malignant spindle cell neoplasm. Cancer. 1995;76:2217–29.

  79. 79.

    Ong HS, Ji T, Zhang CP, Li J, Wang LZ, Li RR, et al. Head and neck inflammatory myofibroblastic tumor (IMT): evaluation of clinicopathologic and prognostic features. Oral Oncol. 2012;48:141–8.

  80. 80.

    LaVigne AW, Meredith DM, D’Adamo DR, Margalit DN. Treatment-refractory ALK-positive inflammatory myofibroblastic tumour of the oral cavity. BMJ Case Rep. 2018.

  81. 81.

    Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31:509–20.

  82. 82.

    Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001;159:411–5.

  83. 83.

    Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000;157:377–84.

  84. 84.

    Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, et al. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol. 2001;25:1364–71.

  85. 85.

    Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14:569–76.

  86. 86.

    Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol. 2002;15:931–8.

  87. 87.

    Mentzel T, Dry S, Katenkamp D, Fletcher CD. Low-grade myofibroblastic sarcoma: analysis of 18 cases in the spectrum of myofibroblastic tumors. Am J Surg Pathol. 1998;22:1228–38.

  88. 88.

    Chan JYK, Gooi Z, Wong EWY, Ng SK, Tong MCF, Vlantis AC. Low-grade myofibroblastic sarcoma: a population-based study. Laryngoscope. 2017;127:116–21.

  89. 89.

    Fisher C, Myofibrosarcoma. Virchows Arch. 2004;445:215–23.

  90. 90.

    Cai C, Dehner LP, El-Mofty SK. In myofibroblastic sarcomas of the head and neck, mitotic activity and necrosis define grade: a case study and literature review. Virchows Arch. 2013;463:827–36.

  91. 91.

    Montgomery E, Goldblum JR, Fisher C. Myofibrosarcoma: a clinicopathologic study. Am J Surg Pathol. 2001;25:219–28.

  92. 92.

    Qiu X, Montgomery E, Sun B. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts. Hum Pathol. 2008;39:846–56.

  93. 93.

    Fletcher CD, Dal Cin P, de Wever I, Mandahl N, Mertens F, Mitelman F, et al. Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. Am J Pathol. 1999;154:1841–7.

  94. 94.

    Chung EB, Enzinger FM. Infantile fibrosarcoma. Cancer. 1976;38:729–39.

  95. 95.

    Soule EH, Pritchard DJ. Fibrosarcoma in infants and children: a review of 110 cases. Cancer. 1977;40:1711–21.

  96. 96.

    Coffin CM, Jaszcz W, O’Shea PA, Dehner LP. So-called congenital-infantile fibrosarcoma: does it exist and what is it? Pediatr Pathol. 1994;14:133–50.

  97. 97.

    Orbach D, Rey A, Cecchetto G, Oberlin O, Casanova M, Thebaud E, et al. Infantile fibrosarcoma: management based on the European experience. J Clin Oncol. 2010;28:318–23.

  98. 98.

    Orbach D, Brennan B, De Paoli A, Gallego S, Mudry P, Francotte N, et al. Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience. Eur J Cancer. 2016;57:1–9.

  99. 99.

    Sulkowski JP, Raval MV, Browne M. Margin status and multimodal therapy in infantile fibrosarcoma. Pediatr Surg Int. 2013;29:771–6.

  100. 100.

    Cecchetto G, Carli M, Alaggio R, Dall’Igna P, Bisogno G, Scarzello G, et al. Fibrosarcoma in pediatric patients: results of the Italian Cooperative Group studies (1979–1995). J Surg Oncol. 2001;78:225–31.

  101. 101.

    Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19:705–14.

  102. 102.

    Sheng WQ, Hisaoka M, Okamoto S, Tanaka A, Meis-Kindblom JM, Kindblom LG, et al. Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol. 2001;115:348–55.

  103. 103.

    Hung YP, Fletcher CDM, Hornick JL. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology. 2018;73:634–44.

  104. 104.

    Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184–7.

  105. 105.

    Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24:937–46.

  106. 106.

    Church AJ, Calicchio ML, Nardi V, Skalova A, Pinto A, Dillon DA, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;31:463–73.

  107. 107.

    Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, et al. Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors. Am J Surg Pathol. 2018;42:927–35.

  108. 108.

    Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, et al. Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol. 2019;43:435–45.

  109. 109.

    Kao Y-C, Fletcher CDM, Alaggio R, Wexler L, Zhang L, Sung Y-S, et al. Recurrent BRAF gene fusions in a subset of pediatric spindle cell sarcomas: expanding the genetic spectrum of tumors with overlapping features with infantile fibrosarcoma. Am J Surg Pathol. 2018;42:28–38.

  110. 110.

    Wegert J, Vokuhl C, Collord G, Del Castillo Velasco-Herrera M, Farndon SJ, Guzzo C, et al. Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun. 2018;9:2378.

  111. 111.

    Flucke U, van Noesel MM, Wijnen M, Zhang L, Chen C-L, Sung Y-S, et al. TFG-MET fusion in an infantile spindle cell sarcoma with neural features. Genes Chromosom Cancer. 2017;56:663–7.

  112. 112.

    Evans HL. Low-grade fibromyxoid sarcoma. A report of 12 cases. Am J Surg Pathol. 1993;17:595–600.

  113. 113.

    Evans HL. Low-grade fibromyxoid sarcoma: a clinicopathologic study of 33 cases with long-term follow-up. Am J Surg Pathol. 2011;35:1450–62.

  114. 114.

    Folpe AL, Lane KL, Paull G, Weiss SW. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes: a clinicopathologic study of 73 cases supporting their identity and assessing the impact of high-grade areas. Am J Surg Pathol. 2000;24:1353–60.

  115. 115.

    Guillou L, Benhattar J, Gengler C, Gallagher G, Ranchère-Vince D, Collin F, et al. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol. 2007;31:1387–402.

  116. 116.

    Billings SD, Giblen G, Fanburg-Smith JC. Superficial low-grade fibromyxoid sarcoma (Evans tumor): a clinicopathologic analysis of 19 cases with a unique observation in the pediatric population. Am J Surg Pathol. 2005;29:204–10.

  117. 117.

    Cowan ML, Thompson LD, Leon ME, Bishop JA. Low-grade fibromyxoid sarcoma of the head and neck: a clinicopathologic series and review of the literature. Head Neck Pathol. 2016;10:161–6.

  118. 118.

    Doyle LA, Möller E, Dal Cin P, Fletcher CDM, Mertens F, Hornick JL. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2011;35:733–41.

  119. 119.

    Reid R, de Silva MVC, Paterson L, Ryan E, Fisher C. Low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes share a common t(7;16)(q34;p11) translocation. Am J Surg Pathol. 2003;27:1229–36.

  120. 120.

    Mertens F, Fletcher CDM, Antonescu CR, Coindre J-M, Colecchia M, Domanski HA, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest. 2005;85:408–15.

  121. 121.

    Panagopoulos I, Storlazzi CT, Fletcher CDM, Fletcher JA, Nascimento A, Domanski HA, et al. The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosom Cancer. 2004;40:218–28.

  122. 122.

    Lau PPL, Lui PCW, Lau GTC, Yau DTW, Cheung ETY, Chan JKC. EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2013;37:734–8.

  123. 123.

    Meis-Kindblom JM, Kindblom LG, Enzinger FM. Sclerosing epithelioid fibrosarcoma. A variant of fibrosarcoma simulating carcinoma. Am J Surg Pathol. 1995;19:979–93.

  124. 124.

    Antonescu CR, Rosenblum MK, Pereira P, Nascimento AG, Woodruff JM. Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol. 2001;25:699–709.

  125. 125.

    Prieto-Granada C, Zhang L, Chen H-W, Sung Y-S, Agaram NP, Jungbluth AA, et al. A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low-grade fibromyxoid sarcoma: a pathologic and molecular study of 18 cases. Genes Chromosom Cancer. 2015;54:28–38.

  126. 126.

    Folk GS, Williams SB, Foss RB, Fanburg-Smith JC. Oral and maxillofacial sclerosing epithelioid fibrosarcoma: report of five cases. Head Neck Pathol. 2007;1:13–20.

  127. 127.

    Eyden BP, Manson C, Banerjee SS, Roberts IS, Harris M. Sclerosing epithelioid fibrosarcoma: a study of five cases emphasizing diagnostic criteria. Histopathology. 1998;33:354–60.

  128. 128.

    Wojcik JB, Bellizzi AM, Dal Cin P, Bredella MA, Fletcher CDM, Hornicek FJ, et al. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series. Am J Surg Pathol. 2014;38:1538–44.

  129. 129.

    Doyle LA, Wang W-L, Dal Cin P, Lopez-Terrada D, Mertens F, Lazar AJF, et al. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am J Surg Pathol. 2012;36:1444–51.

  130. 130.

    Arbajian E, Puls F, Magnusson L, Thway K, Fisher C, Sumathi VP, et al. Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2014;38:801–8.

  131. 131.

    Arbajian E, Puls F, Antonescu CR, Amary F, Sciot R, Debiec-Rychter M, et al. In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets. Clin Cancer Res. 2017;23:7426–34.

  132. 132.

    Kao Y-C, Lee J-C, Zhang L, Sung Y-S, Swanson D, Hsieh T-H, et al. Recurrent YAP1 and KMT2A gene rearrangements in a subset of MUC4-negative sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2019.

Download references

Author information

Correspondence to Jason L. Hornick.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baranov, E., Hornick, J.L. Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck. Head and Neck Pathol (2020) doi:10.1007/s12105-019-01104-3

Download citation


  • Soft tissue tumors
  • Beta-catenin
  • STAT6
  • MUC4
  • NTRK
  • Translocation